A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced ER+, HER2-Negative Breast Cancer
Interventions: DRUG: Elacestrant
Sponsor: Stemline Therapeutics, Inc.